Credit Suisse Group Boosts Teladoc Health (NYSE:TDOC) Price Target to

Teladoc Health (NYSE:TDOC) had its price target upped by Credit Suisse Group from to in a research note issued to investors on Monday morning, The Fly reports.

Several other equities research analysts have also recently commented on the company. SunTrust Banks reissued a hold rating and issued a $80.00 target price on shares of Teladoc Health in a research note on Monday, December 2nd. JPMorgan Chase & Co. lifted their target price on Teladoc Health from $82.00 to $83.00 and gave the company an overweight rating in a research note on Thursday, September 19th. Stifel Nicolaus initiated coverage on Teladoc Health in a research note on Monday, November 25th. They issued a hold rating and a $83.00 target price for the company. Bank of America cut Teladoc Health from a buy rating to a neutral rating and lifted their target price for the company from $82.00 to $90.00 in a research note on Thursday, January 9th. Finally, Royal Bank of Canada initiated coverage on Teladoc Health in a research note on Wednesday, November 27th. They issued an outperform rating and a $100.00 target price for the company. Nine research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $87.71.

NYSE TDOC opened at $94.00 on Monday. The stock has a fifty day moving average of $82.71 and a 200-day moving average of $72.24. The stock has a market capitalization of $6.80 billion, a P/E ratio of -65.28 and a beta of 1.38. Teladoc Health has a 52 week low of $48.57 and a 52 week high of $98.97. The company has a debt-to-equity ratio of 0.44, a quick ratio of 6.55 and a current ratio of 6.55.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, October 30th. The health services provider reported ($0.28) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.12. The company had revenue of $137.96 million during the quarter, compared to analysts’ expectations of $136.46 million. Teladoc Health had a negative return on equity of 11.23% and a negative net margin of 20.15%. The business’s revenue for the quarter was up 24.3% on a year-over-year basis. During the same period last year, the firm earned ($0.34) EPS. Equities research analysts forecast that Teladoc Health will post -1.55 earnings per share for the current fiscal year.

In other Teladoc Health news, insider Lewis Levy sold 2,025 shares of Teladoc Health stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $80.50, for a total transaction of $163,012.50. Following the transaction, the insider now directly owns 5,655 shares in the company, valued at $455,227.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Adam C. Vandervoort sold 3,525 shares of Teladoc Health stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $79.12, for a total value of $278,898.00. Following the transaction, the insider now owns 1,114 shares in the company, valued at $88,139.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 68,099 shares of company stock valued at $5,151,311. 3.14% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of TDOC. CNB Bank lifted its holdings in shares of Teladoc Health by 100.0% in the third quarter. CNB Bank now owns 400 shares of the health services provider’s stock valued at $27,000 after purchasing an additional 200 shares in the last quarter. Capital Investment Advisory Services LLC lifted its holdings in shares of Teladoc Health by 800.0% in the third quarter. Capital Investment Advisory Services LLC now owns 450 shares of the health services provider’s stock valued at $30,000 after purchasing an additional 400 shares in the last quarter. Marshall Wace North America L.P. bought a new stake in shares of Teladoc Health in the first quarter valued at about $35,000. Quadrant Capital Group LLC lifted its holdings in shares of Teladoc Health by 32.4% in the third quarter. Quadrant Capital Group LLC now owns 621 shares of the health services provider’s stock valued at $41,000 after purchasing an additional 152 shares in the last quarter. Finally, American National Bank bought a new stake in shares of Teladoc Health in the third quarter valued at about $54,000.

Teladoc Health Company Profile

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Featured Article: What sectors are represented in the Nikkei Index?

The Fly

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.